Thailand · Delayed Price · Currency is THB DOD Biotech PCL Statistics
Total Valuation
DOD Biotech PCL has a market cap or net worth of THB 698.14 million. The enterprise value is 707.97 million.
| Market Cap | 698.14M |
| Enterprise Value | 707.97M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Mar 13, 2026 |
Share Statistics
DOD Biotech PCL has 450.41 million shares outstanding. The number of shares has decreased by -0.55% in one year.
| Current Share Class | 450.41M |
| Shares Outstanding | 450.41M |
| Shares Change (YoY) | -0.55% |
| Shares Change (QoQ) | -0.89% |
| Owned by Insiders (%) | 12.77% |
| Owned by Institutions (%) | 19.52% |
| Float | 348.79M |
Valuation Ratios
The trailing PE ratio is 57.17.
| PE Ratio | 57.17 |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 67.37 |
| EV / Sales | 1.24 |
| EV / EBITDA | 17.15 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.28 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 1.62 |
| Debt / FCF | -0.65 |
| Interest Coverage | -0.41 |
Financial Efficiency
Return on equity (ROE) is 1.38% and return on invested capital (ROIC) is -0.16%.
| Return on Equity (ROE) | 1.38% |
| Return on Assets (ROA) | -0.08% |
| Return on Invested Capital (ROIC) | -0.16% |
| Return on Capital Employed (ROCE) | -0.13% |
| Weighted Average Cost of Capital (WACC) | 8.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.87 |
Taxes
| Income Tax | -10.55M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.36% in the last 52 weeks. The beta is 0.77, so DOD Biotech PCL's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -14.36% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 33.66 |
| Average Volume (20 Days) | 312,419 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DOD Biotech PCL had revenue of THB 570.53 million and earned 10.51 million in profits. Earnings per share was 0.02.
| Revenue | 570.53M |
| Gross Profit | 190.22M |
| Operating Income | -1.35M |
| Pretax Income | 2.28M |
| Net Income | 10.51M |
| EBITDA | 40.44M |
| EBIT | -1.35M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 52.64 million in cash and 66.94 million in debt, with a net cash position of -14.30 million or -0.03 per share.
| Cash & Cash Equivalents | 52.64M |
| Total Debt | 66.94M |
| Net Cash | -14.30M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | 935.02M |
| Book Value Per Share | 2.09 |
| Working Capital | 268.08M |
Cash Flow
In the last 12 months, operating cash flow was -9.30 million and capital expenditures -94.01 million, giving a free cash flow of -103.31 million.
| Operating Cash Flow | -9.30M |
| Capital Expenditures | -94.01M |
| Depreciation & Amortization | 41.79M |
| Net Borrowing | 21.88M |
| Free Cash Flow | -103.31M |
| FCF Per Share | -0.23 |
Margins
Gross margin is 33.34%, with operating and profit margins of -0.24% and 1.84%.
| Gross Margin | 33.34% |
| Operating Margin | -0.24% |
| Pretax Margin | 0.40% |
| Profit Margin | 1.84% |
| EBITDA Margin | 7.09% |
| EBIT Margin | -0.24% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 3.13%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 3.13% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.55% |
| Shareholder Yield | 3.68% |
| Earnings Yield | 1.51% |
| FCF Yield | -14.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |